TransMedics is helping improve organ transplantation thanks to its innovative organ storage system.
The company has posted strong financial results over the past few years, and the stock is soaring.
But it faces some risks that investors should seriously consider before hitting the “buy” button.
Innovations often (but not always) drive life-changing returns for the companies that engineer them and the people who get in on the ground floor. That’s why investors should sometimes look toward smaller, innovative companies, as some have highly attractive upside potential.
One such corporation to consider is TransMedics Group (NASDAQ: TMDX), which is helping revolutionize the organ transplant market. For those with $5,000 to spare (outside of your emergency fund), here’s why investing that money in TransMedics Group could lead to monster returns.
Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
Storing organs for transplants isn’t easy. The traditional cold storage method has significant drawbacks. Many (in some cases, most) organs that are kept and transported that way end up deteriorating and becoming unusable for transplant. That’s a problem, considering there aren’t enough organs available for transplants.
TransMedics developed its Organ Care System (OCS), devices that mimic the physiology of the human body to help keep organs in good-enough shape for longer. The result? Fewer organs deteriorate, and more of them are saved for patients. The OCS is approved for heart, lung, and liver transplants.
How does it compare to cold storage? The OCS’s utilization for livers, hearts, and lungs is 98%, 97%, and 96%, respectively. In cold storage, utilization for these three organs is 61%, 24%, and 20%, respectively. TransMedics Group has created a better mousetrap, and the company has been rewarded for it. The company’s revenue and earnings have increased rapidly in recent years.
TMDX Revenue (Quarterly) data by YCharts
It has encountered some issues, including problems with organ transport. TransMedics’ reliance on third-party charter aircraft came with a host of headwinds, including delays, pilot shortages, and others. However, the medical device manufacturer has since built its own dedicated transportation network that has helped it address these problems.
TransMedics could see its revenue and earnings continue moving in the right direction, along with the organ transplant market. And if it captures a higher share of that space, its stock price could soar. Further, it is developing newer versions of its OCS for the heart, liver, and lungs, aiming to eventually target other organs.
However, there are some risks. For instance, developing these organ transplant systems isn’t easy and requires jumping through regulatory hoops. Setbacks here could sink the stock, especially since the company will need to stay innovative to remain competitive in this niche of the healthcare industry.
TransMedics’ fleet of aircraft also isn’t easy or cheap to maintain — while it now has more control over its transportation network, that comes with its own set of risks. Investors should monitor these (and other) potential challenges. But if TransMedics can manage them while increasing its market share, the stock could skyrocket in the next decade or so.
Before you buy stock in TransMedics Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TransMedics Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $519,015!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,086,211!*
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 28, 2026.
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
